In view of the loss of cavin3 in numerous cancers (Carén et al., 2011; Kim et al., 2014; Lee et al., 2008; Lee et al., 2011; Martinez et al., 2009; Tong et al., 2010; Xu et al., 2001; Zöchbauer-Müller et al., 2005) and the crucial role of BRCA1 as a tumor suppressor (King and Marks, 2003; Miki et al., 1994; Venkitaraman, 2002), these studies describing a new functional partner for BRCA1 suggest that cavin3 should be considered in future cancer diagnostic and therapeutic strategies. This evidence concerns the gene BRCA1 and cancer.